Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2004Molecular Cancer TherapeuticsOpen Access

Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease

View Full Paper
Ask AI
Bookmark
Share

Authors

KKKoji KawakamiMKMariko KawakamiRPRaj K. Puri

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kawakami et al. (2004) studied this question.

synapsesocial.com/papers/6a7010303ce530166bc2b925https://doi.org/10.1158/1535-7163.137.3.2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer2002 · 2,949 citations
  2. 2Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies2001 · 87 citations
  3. 3Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: Comparison between IL-4- and IL-13-induced signal transduction1997 · 63 citations
  4. 4A Novel Chimeric Protein Composed of Interleukin 13 and Pseudomonas Exotoxin Is Highly Cytotoxic to Human Carcinoma Cells Expressing Receptors for Interleukin 13 and Interleukin 41995 · 212 citations
  5. 5Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft2000 · 62 citations